Article
Pseudocannabinoid H4CBD enhances lipid catabolism to reduce visceral adiposity and large adipocyte size in advanced metabolic syndrome
2025-08-19
Abstract excerpt
<title>Abstract</title> <p> Background Metabolic Syndrome (MetS) is a precursor for cardiovascular disease (CVD) and type 2 diabetes (T2D) and has a prevalence of 55% among people ≥ 60 years of age in the US. Cannabidiol (CBD) use has grown more popular in the last two decades, particularly amongst adults > 55 years of age. Synthetic analogues of CBD have generated great interest because they can offer safer, ch...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cf02cfbd-2f27-52f2-aad6-db2960b1627e
- DOI
- 10.21203/rs.3.rs-7274449/v1
